Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,300 shares, a decline of 88.7% from the November 30th total of 20,400 shares. Based on an average daily trading volume, of 198,200 shares, the short-interest ratio is presently 0.0 days.

Chugai Pharmaceutical Price Performance

CHGCY stock traded down $0.06 on Thursday, reaching $21.95. The company's stock had a trading volume of 78,931 shares, compared to its average volume of 127,127. Chugai Pharmaceutical has a 52 week low of $14.52 and a 52 week high of $26.00. The company has a market capitalization of $72.24 billion, a P/E ratio of 28.14 and a beta of 0.82. The firm has a fifty day moving average of $22.47 and a two-hundred day moving average of $21.74.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.